Everest Medicines (HKSE:01952) Cash-to-Debt : 2.92 (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Everest Medicines Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Everest Medicines's cash to debt ratio for the quarter that ended in Dec. 2024 was 2.92.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Everest Medicines could pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.

The historical rank and industry rank for Everest Medicines's Cash-to-Debt or its related term are showing as below:

HKSE:01952' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.33 Med: 5.44 Max: 20.74
Current: 2.92

During the past 7 years, Everest Medicines's highest Cash to Debt Ratio was 20.74. The lowest was 0.33. And the median was 5.44.

HKSE:01952's Cash-to-Debt is ranked worse than
62.02% of 1464 companies
in the Biotechnology industry
Industry Median: 7.685 vs HKSE:01952: 2.92

Everest Medicines Cash-to-Debt Historical Data

The historical data trend for Everest Medicines's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Everest Medicines Cash-to-Debt Chart

Everest Medicines Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash-to-Debt

Get a 7-Day Free Trial

10.02

5.44

20.74

4.60

2.92

Everest Medicines Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Cash-to-Debt	Get a 7-Day Free Trial							20.74	8.81	4.60	3.62	2.92

Competitive Comparison of Everest Medicines's Cash-to-Debt

For the Biotechnology subindustry, Everest Medicines's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Everest Medicines's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Everest Medicines's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Everest Medicines's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

Everest Medicines Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Everest Medicines's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1711.807	/	(493.932	+	92.479)
	=	2.92

Everest Medicines's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1711.807	/	(493.932	+	92.479)
	=	2.92

Everest Medicines (HKSE:01952) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Everest Medicines Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Everest Medicines's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Everest Medicines Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Everest Medicines Ltd (HKSE:01952) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

6HN:Germany

Address

1168 West Nanjing Road, 16th Floor, CITIC Pacific Plaza, Jing’an District, Shanghai, CHN, 200041

Website

https://www.everestmedicines.com

Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others. Geographically operates in Mainland China.

Executives

Fu Wei	2307 Founder of a discretionary trust who can infl
Nova Aqua Limited	2201 Interest of corporation controlled by you
C-bridge Capital Gp Iv, Ltd.	2201 Interest of corporation controlled by you
C-bridge Healthcare Fund Gp Iv, L.p.	2201 Interest of corporation controlled by you
C-bridge Healthcare Fund Iv, L.p.	2201 Interest of corporation controlled by you
Tf Capital Iv Ltd.	2201 Interest of corporation controlled by you
C-bridge Capital Gp, Ltd.	2501 Other
C-bridge Healthcare Fund Gp Ii, L.p.	2501 Other
C-bridge Healthcare Fund Ii, L.p.	2501 Other
C-bridge Investment Everest Limited	2501 Other
Tf Capital Ii Ltd.	2501 Other
Everest Management Holding Co., Ltd.	2101 Beneficial owner
Fu Wei	2307 Founder of a discretionary trust who can infl
C-bridge Joint Value Creation Limited	2201 Interest of corporation controlled by you
Kolchinsky Anna Inge Leonore Haas	2202 Interest of your spouse

Everest Medicines Headlines

No Headlines